Enveric Highlights Preclinical PTSD Data Amid Rising Focus On Mental Health Therapies [Benzinga]
Tuesday, May 5, 2026 1 min read
Key Takeaway: Enveric Biosciences Inc. has reported promising preclinical results for its candidate EB-003, which demonstrated rapid reductions in fear responses associated with PTSD. The findings suggest that a single dose can significantly impact conditioned fear within an hour. This comes at a time when federal policies are increasingly supportive of psychedelic therapies for mental health.
Price reaction · baseline $3.41 (2026-05-04 close) · hit pre-market · 2 other ENVB headline(s) in the window, move may be shared
day 0 close
+2.1%
Market Sentiment Analysis
POSITIVE FACTORS
Rapid reductions in PTSD-related fear responses observed.
Single dose of EB-003 showed significant effects within one hour.
Growing federal support for psychedelic-based mental health treatments.
Full Press Release Details
Enveric Biosciences Inc. (NASDAQ:ENVB) on Tuesday highlighted preclinical findings for its lead candidate EB-003. It pointed to rapid reductions in PTSD-related fear responses, as recent federal policy signals growing support for psychedelic-based mental health treatments. The company said a single dose of EB-003 significantly reduced context-induced freezing behavior within one hour in a validated preclinical PTSD model, suggesting a fast-acting impact on conditioned fear responses.
Full Article >>
Frequently Asked Questions
What is EB-003?
EB-003 is Enveric Biosciences' lead candidate targeting PTSD.
How does EB-003 affect PTSD symptoms?
EB-003 significantly reduces context-induced fear responses in preclinical models.
What were the results of the preclinical study?
The study showed rapid reductions in PTSD-related fear responses within one hour.
What is the significance of federal support?
Growing federal support indicates increasing acceptance of psychedelic-based mental health treatments.